SMMT

Summit Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 2/10
  • Value↑ 5/10
Summit Therapeutics sales and earnings growth
SMMT Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -433.33%
  • FCF Y/Y↓ -121.38%
Summit Therapeutics gross and profit margin trends
SMMT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -310.43%
Summit Therapeutics net debt vs free cash flow
SMMT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Summit Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks